Guangdong Zhongsheng Pharmaceutical (002317.SZ): RAY1225 injection approved to conduct Phase II clinical trials for overweight or obese indications in the United States.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Ruichuang"), has received approval from the U.S. Food and Drug Administration (FDA) to proceed with a clinical trial for its innovative peptide drug RAY1225 injection. The FDA issued a Study May Proceed Letter, allowing the RAY1225 injection to be directly tested in the United States for phase II clinical trials for overweight or obese indications. RAY1225 injection is a novel peptide drug developed by Ruichuang with global independent intellectual property rights. It belongs to the long-acting GLP-1 class of drugs with dual activation of GLP-1 receptor and GIP receptor. It can regulate metabolism and control blood sugar by stimulating insulin secretion, slowing gastric emptying, and other mechanisms. It is expected to be used in the treatment of various metabolic disorders such as blood sugar reduction, weight loss, and metabolic syndrome.